肺纤维化患者血清中IL-9、IL-10、PU.1水平及其临床意义

目的研究特发性肺纤维化(IPF)患者血清中白细胞介素-9(IL-9)、白细胞介素-10(IL-10)、转录因子PU.1水平的变化,探讨其在肺纤维化中的作用。方法采用荧光定量逆转录聚合酶链反应法分别检测IPF患者30例,健康对照者25例血清中IL-9、IL-10及PU.1mRNA表达水平。结果 (1)IPF组患者血清IL-9水平明显高于对照组(P0.01)。(2)IPF组患者血清IL-10明显低于对照组(P0.01)。(3)IPF组患者血清PU.1水平高于对照组(P0.05)。(4)IL-9与IL-10表达呈负相关(r=-0.778,P0.05)。结论IL-9、IL-10、PU.1参与IPF的发病过程,联合检测这三种因子对于IPF发病机制的探索及临床诊治具有重要意义。     

蒲元胃康治疗慢性胃炎的效果

1目的　观察蒲元胃康治疗慢性胃炎的效果。 2方法　将纤维胃镜和病理检查确诊为慢性胃炎的10 0例病人随机分为 2组 ,采用双盲给药法。治疗组 5 6例 ,服蒲元胃康 ;对照组 44例 ,服含淀粉的安慰剂。 3结果治疗组 5 6例中 ,5 3例症状改善 ,总有效率为 94.6 % ,明显高于对照组 (18.2 % ) ,差异有极显著性 (χ2 =6 6 .33,P<0 .0 1) ;治疗组浅表性胃炎 35例中 ,2 8例病理改善 ,总有效率为 80 .0 % ,明显高于对照组 (2 1.4% ) ,差异有极显著性(χ2 =2 2 .6 2 ,P<0 .0 1) ;治疗组萎缩性胃炎 2 1例中 ,13例病理改善 ,总有效率为 6 1.9% ,明显高于对照组 (19.8% ) ,差异有极显著性 (直接概率 P=0 .0 0 9) ;治疗组幽门螺杆菌阴转 19例 ,有效 16例 ,总有效率为 6 2 .5 % ,明显高于对照组 (11.4% ) ,差异有极显著性 (χ2 =2 7.76 ,P<0 .0 0 1)。 4结论　蒲元胃康是一纯中药制剂 ,治疗慢性胃炎的效果好、副作用少、服药方便 ,值得临床推广应用     

Interventions to improve uptake of rubella immunization

Uptake rate of immunization against rubella, by schoolgirls, in the Harrogate HealthDistrict was only 85% in 1982/83. A previous study demonstrated that a history of previous rubella was the most frequent reason given for not accepting the offer of immunization. The existence of an option for schoolgirls to attend their general practitioners was also found to be an important contributor to non-acceptance. Following changes in health education and follow-up of girls electing to attend GPs the uptake rate improved to 92%.     

医用高分子材料在医疗器械中的应用

本文论述了医用高分子材料的发展概况，主要介绍了聚氯酯、聚氯乙烯、硅橡胶材料的特性及其在医疗器械中的应用。     

Protective role of puerarin on lead-induced alterations of the hepatic glutathione antioxidant system and hyperlipidemia in rats

Puerarin (PU), a natural flavonoid, has been reported to have many benefits and medicinal properties. The aim of the present study was to investigate the effects of puerarin on hepatic oxidative stress and hyperlipidemia in rats exposed to lead. Our data showed that puerarin significantly prevented lead-induced hepatotoxicity, indicated by both diagnostic indicators of liver damage (serum aminotransferase levels) and histopathological analysis. Moreover, lead-induced profound elevation of ROS production and oxidative stress, as evidenced by increasing of lipid peroxidation level, reducing of GPx, GST, GR and GCL activities and depleting of intracellular reduced GSH level in liver, were suppressed by treatment with puerarin. Furthermore, the increase of serum cholesterol, triglycerides and LDL induced by lead was effectively suppressed by puerarin. The HDL level in the lead treatment rats was also increased by puerarin. Western blot analysis showed that puerarin remarkably inhibited hyperlipidemia by regulating the expression of cholesterol 7a-hydroxylase (CYP7A1), 3-hydroxy-3-methylglutaryl-CoA reductase (HMGR) and low-density lipoprotein receptor (LDL-R) in liver of lead treated rats. Altogether, these results suggest that puerarin could protect the lead-induced liver injury and hyperlipidemia by reducing ROS production, renewing the activities of antioxidant enzymes and influencing expression of hepatic lipid biosynthesis and metabolism genes.